Sanofi Total Assets 2011-2025 | SNY
Sanofi total assets from 2011 to 2025. Total assets can be defined as the sum of all assets on a company's balance sheet.
- Sanofi total assets for the quarter ending September 30, 2025 were $151.716B, a 0% increase year-over-year.
- Sanofi total assets for 2024 were $143.701B, a 4.99% increase from 2023.
- Sanofi total assets for 2023 were $136.872B, a 2.51% increase from 2022.
- Sanofi total assets for 2022 were $133.514B, a 6.15% decline from 2021.
|
Sanofi Annual Total Assets (Millions of US $) |
|
|---|---|
| 2024 | $143,701 |
| 2023 | $136,872 |
| 2022 | $133,514 |
| 2021 | $142,258 |
| 2020 | $130,827 |
| 2019 | $126,264 |
| 2018 | $131,573 |
| 2017 | $112,833 |
| 2016 | $115,830 |
| 2015 | $113,617 |
| 2014 | $129,463 |
| 2013 | $127,603 |
| 2012 | $129,133 |
| 2011 | $139,510 |
| 2010 | $113,222 |
|
Sanofi Quarterly Total Assets (Millions of US $) |
|
|---|---|
| 2025-09-30 | $151,716 |
| 2025-06-30 | $141,854 |
| 2025-03-31 | $138,948 |
| 2024-12-31 | $143,701 |
| 2024-09-30 | $0 |
| 2024-06-30 | $139,733 |
| 2024-03-31 | $0 |
| 2023-12-31 | $136,872 |
| 2023-09-30 | $0 |
| 2023-06-30 | $136,685 |
| 2023-03-31 | $0 |
| 2022-12-31 | $133,514 |
| 2022-09-30 | $0 |
| 2022-06-30 | $129,647 |
| 2022-03-31 | $0 |
| 2021-09-30 | $0 |
| 2021-03-31 | $0 |
| 2020-09-30 | $0 |
| 2020-03-31 | $0 |
| 2019-09-30 | $0 |
| 2019-03-31 | $0 |
| 2018-03-31 | $0 |
| 2017-12-31 | $112,833 |
| 2017-09-30 | $0 |
| 2017-06-30 | $112,077 |
| 2017-03-31 | $0 |
| 2016-12-31 | $115,830 |
| 2016-09-30 | $0 |
| 2016-06-30 | $111,958 |
| 2016-03-31 | $0 |
| 2015-09-30 | $0 |
| 2015-06-30 | $108,322 |
| 2014-06-30 | $124,450 |
| 2013-06-30 | $126,655 |
| 2012-06-30 | $130,750 |
| 2012-03-31 | $0 |
| 2011-12-31 | $139,510 |
| 2011-09-30 | $0 |
| 2011-06-30 | $143,306 |
| 2011-03-31 | $0 |
| 2010-12-31 | $113,222 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $128.030B | $44.458B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $969.283B | 46.62 |
| Johnson & Johnson (JNJ) | United States | $472.053B | 18.88 |
| AbbVie (ABBV) | United States | $410.669B | 24.59 |
| Roche Holding AG (RHHBY) | Switzerland | $286.026B | 0.00 |
| Novartis AG (NVS) | Switzerland | $277.276B | 14.70 |
| Merck (MRK) | United States | $230.630B | 10.74 |
| Novo Nordisk (NVO) | Denmark | $215.481B | 12.63 |
| Pfizer (PFE) | United States | $142.484B | 7.83 |
| Bayer (BAYRY) | Germany | $32.184B | 5.65 |
| Innoviva (INVA) | United States | $1.664B | 8.33 |